Literature DB >> 21466497

Genetics and ulcerative colitis: what are the clinical implications?

Anna Latiano1, Vito Annese.   

Abstract

Substantial progress has been made in the last years in characterizing the susceptibility genes involved in IBD pathogenesis, especially for Crohn's disease. Although some genetic factors associated with Crohn's disease also predispose individuals to ulcerative colitis, markers specific only for ulcerative colitis have been found. Recent genome-wide association studies in ulcerative colitis have identified several new loci, and suggested many new potential pathways. The identified susceptibility genes and their variants could be useful to predict disease course and to improve stratification of patients, when correlated with other subphenotypes. Moreover, understanding the biological pathways involved in the disease could lead to the development of new treatments and molecules that specifically target such pathways, discover different therapeutic approaches and eventually progress to personalized treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21466497     DOI: 10.2174/138945011796818171

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  3 in total

1.  No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects.

Authors:  Mustafa Hartavi; Selim Giray Nak; Barbaros Oral; Adem Deligönül
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

2.  Difference in DRB1* gene polymorphisms between Han and Uyghur ulcerative colitis patients in China.

Authors:  Ayinuer Aheman; Feng Gao; Aihemaijiang Kuerbanjiang; Yue-Xian Li; Mireayi Abuduhadeer
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

3.  Association of fucosyltransferase 2 gene variants with ulcerative colitis in Han and Uyghur patients in China.

Authors:  Ayinuer Aheman; He-Sheng Luo; Feng Gao
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.